Mirati sets sights on adagrasib accelerated approval following ESMO22 readout

With longer-term follow up for KRAS inhibitor adagrasib in a cohort of colorectal cancer patients, Mirati maintains its edge over competitors in an indication where accelerated approval is still in play.

In a late-breaking abstract released on Wednesday ahead of the European Society of Medical Oncology (ESMO) meeting in Paris, Mirati Therapeutics Inc. (NASDAQ:MRTX) announced that adagrasib plus EGFR inhibitor Erbitux cetuximab led to an ORR of 46% and a median PFS of 6.9 months after more than 17 months of follow-up in the Krystal-1 study. ...